Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

WuXi STA’s Jinshan Site Passes Fourth U.S. FDA Inspection

By STA Pharmaceutical Co., Ltd. | July 27, 2018

WuXi STA’s Jinshan site in Shanghai, China

The STA Pharmaceutical Co., Ltd. Active Pharmaceutical Ingredient (API) manufacturing facility at Jinshan in Shanghai, China, has successfully passed its fourth inspection from the U.S. Food and Drug Administration (FDA)—with no Form 483s issued. The site previously passed three FDA inspections in 2013, 2014 and 2016. STA Pharmaceutical, also referred to as WuXi STA, is a subsidiary of WuXi AppTec.

WuXi STA is the first CDMO in China that is approved to supply commercial APIs for innovative drugs by regulatory agencies in the U.S., China, EU, Canada, Switzerland, Australia, and New Zealand.

The Jinshan site, which opened in 2004, is equipped with 100+ modern reactors ranging from 5L to 20,000L, as well as technology platforms such as flow chemistry, biocatalysis, and high potency APIs. The Jinshan facility is dedicated to the manufacture of small molecule APIs and advanced intermediates, from kilo to metric ton scale—from preclinical and clinical development through to global commercial launch.

In addition, WuXi STA recently initiated the site expansion project in Jinshan, adding more than 30,000 square meters of laboratory space and 500 scientists. Upon completion, the expanded campus will be able to offer one-site process development and manufacturing of APIs and advanced intermediates, according to the company.

The WuXi subsidiary has operations in China and the U.S. along with global partnerships.

(Source: WuXi AppTec; STA Pharmaceutical Co., Ltd.)

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE